Treatment
Cell clinical trials
We’re tracking 5,545 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT05837221Recruiting
Study of the mouth microbiome in oral cancer
This study looks at the types of bacteria in the mouth (the microbiome) in people with oral squamous cell cancer and compares them to people without this cancer. It may help researchers understand what’s different in oral cancer and what could be useful for diagnosis or treatment planning.
Aurora, ColoradoAges 18–100 - NCT05838391Recruiting
Targeted radiation approach for anal cancer
This trial tests an adaptive, image-guided radiation plan for anal canal squamous-type cancers. It may help deliver effective treatment while adjusting the radiation based on how your body and tumor respond.
New York, New YorkAges 18 years+ - NCT05815173RecruitingPhase 1
Ladarixin plus sotorasib for KRAS-mutated lung cancer
This Phase 1 trial tests whether ladarixin combined with sotorasib can help people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation. It’s mainly testing safety and how well the treatments work after the cancer has progressed despite prior anti–PD-1 treatment.
Garden City, New YorkAges 18–100 - NCT05805631RecruitingPhase 2
Pemetrexed into spinal fluid for EGFR-mutant lung cancer spread to brain lining
This Phase 2 trial tests giving pemetrexed directly into the spinal fluid to treat cancer that has spread to the brain’s and spinal cord’s lining (leptomeningeal metastasis). It is for people with EGFR-mutant non-squamous lung cancer whose disease progressed after osimertinib, and who may benefit from a targeted treatment delivered to the area affected in the brain lining.
Taipei, TaiwanAges 20 years+ - NCT03999229RecruitingPhase 1
Nitric-oxide therapy during your own blood return
This early study tests whether a nitric-oxide–based treatment (given during autologous blood transfusion) can affect how well your body handles the returned blood. It mainly needs healthy adults who can safely donate blood and follow medication and breathing/comfort requirements.
Cleveland, OhioAges 18–35 - NCT05809284Recruiting
Understanding CAR T-cell therapy persistence in young patients with ALL
This study looks at why CAR T-cell therapy stops working in some children and young adults with leukemia. It aims to help doctors understand how to make this treatment last longer.
LondonAges Up to 25 years - NCT05802186Recruiting
AI-guided radiation plan for lung cancer tumors
This study uses an AI tool to help plan how doctors deliver focused radiation to lung tumors. It may help make radiation targeting more precise and support treatment safety for people with primary or limited metastatic lung cancer.
Chicago, IllinoisAges 18 years+ - NCT05798845RecruitingPhase 2
Toripalimab plus radiation before surgery for stage II–IIIA lung cancer
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05805371RecruitingPhase 1
PSCA CAR-T cells with or without radiation for prostate cancer
This Phase 1 study tests a prostate cancer treatment made of PSCA-targeted CAR-T cells, with or without radiation, to help control advanced prostate cancer. It aims to find a safe treatment approach and see how well it works in people whose cancer has PSCA.
Duarte, CaliforniaAges 18 years+ - NCT05807932RecruitingPhase 1/Phase 2
Venetoclax added to conditioning before stem cell transplant
This trial tests adding venetoclax to a standard “conditioning” chemotherapy plan before an allogeneic stem cell transplant (using a donor) for certain bone marrow cancers. It aims to improve how well the transplant works and how safe this combination is for people with MDS, CMML, or sAML.
Aachen, North Rhine-WestphaliaAges 18 years+ - NCT05786040RecruitingPhase 2
Tafasitamab plus rituximab for PTLD after solid organ transplant
This trial studies tafasitamab plus rituximab to treat a type of lymphoma called post-transplant lymphoproliferative disorder (PTLD) in adults after a solid organ transplant. It’s aimed at helping stop the PTLD when it can be measured and before you’ve had PTLD treatment beyond limited measures like steroid or reducing anti-rejection drugs.
New Brunswick, New JerseyAges 18 years+ - NCT05782335Recruiting
Study immune cell changes with Orencia in rheumatoid arthritis
This trial studies how Orencia (abatacept) affects your immune system’s T and B cells in people with rheumatoid arthritis. It may help researchers better understand who responds to Orencia and what immune changes happen over time.
New York, New YorkAges 18 years+ - NCT05793151Recruiting
Guided care to start cancer treatment on time after surgery
This trial tests a navigation program (help from a care coordinator) versus usual care to help people start the recommended “next-step” treatments (like radiation, sometimes with chemo) on time after surgery. It’s for certain stages of squamous cell cancer in the head and neck area where late treatment could matter.
St Louis, MissouriAges 18 years+ - NCT05808920Recruiting
Salvage surgery study for recurrent head and neck skin-cell cancer
This study looks at how well people do after “salvage” surgery (planned surgery after prior treatment) for recurrent or residual squamous cell cancer in the head and neck. It may help doctors understand which patients benefit most, including how this surgery affects survival and day-to-day function.
DerbyAges 18 years+ - NCT05810181Recruiting
Interviews to improve choices about gene therapy for rare diseases
This study uses one-on-one interviews to learn what families and clinicians need to make decisions about gene therapy for rare diseases. The goal is to create or improve decision tools that make gene therapy information easier to understand and act on.
Memphis, TennesseeAges 8 years+ - NCT05797168RecruitingPhase 1/Phase 2
Early study drug for advanced solid tumors, alone or with another drug
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
Duarte, CaliforniaAges 18–130 - NCT05777993Enrolling by invitationPhase 4
Continued access to mitapivat for prior study participants
This study provides continued access to the drug mitapivat for people who have already been in a mitapativ study and are benefiting from it.
Anderlecht, Brussels CapitalAges 18 years+ - NCT05751798RecruitingPhase 1/Phase 2
Test drug OSE-279 for advanced lung cancer that has no key mutations
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
AnderlechtAges 18 years+ - NCT05751512RecruitingPhase 3
Comparing a new treatment for advanced head and neck cancer that has stopped responding to standard care
This study tests a new drug called MRG003 against two other treatments (cetuximab or methotrexate) for people with a type of head and neck cancer that has come back or spread and has not responded to standard treatments. The goal is to see if the new drug can better control the cancer and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05775224Enrolling by invitation
Join a research data hub for sickle cell or multiple myeloma
This study builds a database of people with sickle cell disease and/or active multiple myeloma (diagnosed or treated in recent years). It may help researchers learn how these illnesses behave and support better future studies or treatments.
Washington D.C., District of ColumbiaAges Any age - NCT05756569RecruitingPhase 2
Enfortumab plus pembrolizumab for advanced bladder cancer variants
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Atlanta, GeorgiaAges 18 years+ - NCT05748197RecruitingPhase 1
Study of ADCLEC.syn1 for relapsed or resistant AML
This Phase 1 study tests ADCLEC.syn1, a new treatment made from a patient’s immune cells, in adults with relapsed or refractory acute myeloid leukemia (AML). The goal is to see how safe it is and how well it may work, especially after standard treatments have not helped.
Basking Ridge, New JerseyAges 18 years+ - NCT05775718RecruitingPhase 2
Shingrix shot after bone marrow transplant to prevent shingles
This Phase 2 study tests whether an additional Shingrix (RZV) vaccine dose helps prevent shingles in people who previously had an allogeneic bone marrow or stem cell transplant. It focuses on people who are at least a year out from their first two Shingrix doses.
Aurora, ColoradoAges 18–79 - NCT05765084RecruitingPhase 1/Phase 2
Atezolizumab plus WT1 vaccine with chemo for pleural mesothelioma
This trial studies a treatment plan that combines an immune drug (atezolizumab) and a personalized cancer vaccine (WT1/DC) with standard first-line chemotherapy for epithelioid malignant pleural mesothelioma that cannot be removed with surgery. It aims to improve control of the cancer by helping the immune system work alongside chemotherapy.
Edegem, AntwerpAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,545 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.